WHO announces acceleration of data exchange between Russia, EU on Sputnik V
Russia and the European Union maintain a constant exchange of data on the Russian Sputnik V vaccine against coronavirus. Today this process has accelerated.
During his speech at the online briefing, Hans Kluge, Director of the Regional Office for Europe of the World Health Organization (WHO), recalled that the EU and Russia held an international forum last week involving representatives from Brussels, Moscow, and members of the European Commission. The issue of vaccines was raised, among other things, at the event.
We see a constant exchange of information between the European Union and Russia on this topic. This process has accelerated thanks to the successful forums held with the participation of Russia's Ministry of Health, Kluge said.
Russia's Health Ministry approved its first vaccine to prevent coronavirus, developed by the Gamaleya Research Center, in August 2020. In October, the ministry registered another domestic vaccine, EpiVacCorona, produced at the Vector Center of Rospotrebnadzor, RIA Novosti reports.
NEWS.ru reported earlier that, according to Bloomberg, the Russian Sputnik V anti-coronavirus vaccine wasn’t included in the top five most demanded drugs in the world.